CA2789006C - Extended release formulations of rasagiline and uses thereof - Google Patents

Extended release formulations of rasagiline and uses thereof Download PDF

Info

Publication number
CA2789006C
CA2789006C CA2789006A CA2789006A CA2789006C CA 2789006 C CA2789006 C CA 2789006C CA 2789006 A CA2789006 A CA 2789006A CA 2789006 A CA2789006 A CA 2789006A CA 2789006 C CA2789006 C CA 2789006C
Authority
CA
Canada
Prior art keywords
salt
weight
rasagiline
active agent
entire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2789006A
Other languages
English (en)
French (fr)
Other versions
CA2789006A1 (en
Inventor
Yoram Sela
Nurit Livnah
Itschak Lamensdorf
Tomer Madmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Two B Ltd
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2789006(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of CA2789006A1 publication Critical patent/CA2789006A1/en
Application granted granted Critical
Publication of CA2789006C publication Critical patent/CA2789006C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2789006A 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof Active CA2789006C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03
US61/301,019 2010-02-03
PCT/IL2011/000126 WO2011095973A1 (en) 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof

Publications (2)

Publication Number Publication Date
CA2789006A1 CA2789006A1 (en) 2011-08-11
CA2789006C true CA2789006C (en) 2018-11-27

Family

ID=43896855

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789006A Active CA2789006C (en) 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof

Country Status (25)

Country Link
US (1) US9943489B2 (enExample)
EP (2) EP2531181B1 (enExample)
JP (3) JP6045347B2 (enExample)
KR (1) KR101791715B1 (enExample)
CN (1) CN102791258B (enExample)
AU (1) AU2011212068B2 (enExample)
BR (1) BR112012019374B1 (enExample)
CA (1) CA2789006C (enExample)
CL (1) CL2012002175A1 (enExample)
CY (1) CY1121781T1 (enExample)
DK (1) DK2531181T3 (enExample)
ES (1) ES2733133T3 (enExample)
HU (1) HUE044221T2 (enExample)
IL (1) IL221274A (enExample)
LT (1) LT2531181T (enExample)
MX (1) MX354423B (enExample)
NZ (1) NZ602111A (enExample)
PL (1) PL2531181T3 (enExample)
PT (1) PT2531181T (enExample)
RS (1) RS58988B1 (enExample)
RU (2) RU2607595C2 (enExample)
SG (1) SG183150A1 (enExample)
TR (1) TR201909277T4 (enExample)
WO (1) WO2011095973A1 (enExample)
ZA (1) ZA201206462B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789006C (en) * 2010-02-03 2018-11-27 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
JP6243351B2 (ja) 2012-01-12 2017-12-06 ファーマ ツゥ ビー リミテッド パーキンソン病の固定投与量薬剤組合せ治療
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
WO2014028868A1 (en) * 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
IN2013MU01782A (enExample) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
CA3064006C (en) * 2017-05-19 2025-09-16 Biscayne Neurotherapeutics Inc Modified release pharmaceutical compositions of huperzine and methods of using the same
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
KR20210005662A (ko) * 2018-04-25 2021-01-14 뉴로센트리아, 인크. 마그네슘 트레오네이트 조성물 및 이의 용도
KR20220015437A (ko) * 2019-05-31 2022-02-08 데날리 테라퓨틱스 인크. 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
EP4337176B1 (en) * 2021-05-11 2025-07-16 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN118680910B (zh) * 2024-08-26 2024-12-03 山东齐都药业有限公司 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
AU1450592A (en) 1991-04-04 1992-11-02 University Of Toronto Innovations Foundation, The Use of deprenyl to maintain, prevent loss, or recover nerve cell function
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
KR20020008167A (ko) 1999-04-29 2002-01-29 플레믹 크리스티안 잠재적 항정신병제로서의 글리신 분해계 저해제
CA2452738C (en) * 2001-07-04 2011-06-14 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
CA2574925A1 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
AR055070A1 (es) * 2005-06-29 2007-08-01 Panacea Biotec Ltd Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
US20070048371A1 (en) * 2005-07-28 2007-03-01 Shojaei Amir H Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) * 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
MX2010013393A (es) 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
CA2789006C (en) * 2010-02-03 2018-11-27 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof

Also Published As

Publication number Publication date
KR101791715B1 (ko) 2017-10-30
EP3517103A1 (en) 2019-07-31
US20120301542A1 (en) 2012-11-29
CL2012002175A1 (es) 2013-01-11
ES2733133T3 (es) 2019-11-27
KR20120130292A (ko) 2012-11-30
SG183150A1 (en) 2012-09-27
ZA201206462B (en) 2014-02-26
MX354423B (es) 2018-03-02
NZ602111A (en) 2014-10-31
JP2019048855A (ja) 2019-03-28
JP6440662B2 (ja) 2018-12-19
BR112012019374A2 (pt) 2016-05-03
AU2011212068B2 (en) 2016-08-18
RU2016141314A3 (enExample) 2019-12-20
RU2734632C2 (ru) 2020-10-21
JP2017031189A (ja) 2017-02-09
TR201909277T4 (tr) 2019-07-22
BR112012019374B1 (pt) 2022-01-11
PT2531181T (pt) 2019-07-17
CY1121781T1 (el) 2020-07-31
IL221274A (en) 2017-05-29
JP6770564B2 (ja) 2020-10-14
RU2016141314A (ru) 2018-12-14
JP2013518870A (ja) 2013-05-23
IL221274A0 (en) 2012-10-31
EP2531181A1 (en) 2012-12-12
JP6045347B2 (ja) 2016-12-14
CN102791258A (zh) 2012-11-21
HUE044221T2 (hu) 2019-10-28
US9943489B2 (en) 2018-04-17
AU2011212068A1 (en) 2012-09-20
RS58988B1 (sr) 2019-08-30
RU2607595C2 (ru) 2017-01-10
CA2789006A1 (en) 2011-08-11
MX2012009079A (es) 2012-12-17
DK2531181T3 (da) 2019-07-15
WO2011095973A1 (en) 2011-08-11
RU2012136723A (ru) 2014-03-10
CN102791258B (zh) 2018-05-08
EP2531181B1 (en) 2019-04-10
PL2531181T3 (pl) 2019-09-30
LT2531181T (lt) 2019-07-10

Similar Documents

Publication Publication Date Title
CA2789006C (en) Extended release formulations of rasagiline and uses thereof
AU2018202002B2 (en) Methods and compositions for treatment of attention deficit disorder
US10561602B2 (en) Controlled extended release pregabalin
AU2010277207A1 (en) Multi-layered, multiple unit pharmaceutical compositions
EP2802319B1 (en) Fixed dose combination therapy of parkinson's disease
US20140112995A1 (en) Multi-layered, multiple unit pharmaceutical compositions
CA2874677A1 (en) Multi-layered, multiple unit pharmaceutical compositions
HK1203847B (en) Fixed dose combination therapy of parkinson's disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160201